Stockholm - Delayed Quote SEK

Clinical Laserthermia Systems AB (publ) (CLS-B.ST)

2.6200
-0.0850
(-3.14%)
At close: May 23 at 5:22:35 PM GMT+2
Loading Chart for CLS-B.ST
  • Previous Close 2.7050
  • Open 2.7600
  • Bid 2.6900 x --
  • Ask 2.7000 x --
  • Day's Range 2.6200 - 2.7900
  • 52 Week Range 2.4300 - 23.4950
  • Volume 73,659
  • Avg. Volume 108,649
  • Market Cap (intraday) 67.246M
  • Beta (5Y Monthly) 0.03
  • PE Ratio (TTM) --
  • EPS (TTM) -3.0900
  • Earnings Date Aug 15, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 12.00

Clinical Laserthermia Systems AB (publ) engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden. The company offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. It also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers provides multiple options to control treatment. In addition, the company offers various gauge laser applicators, as well as provides temperature and treatment monitoring devices. Clinical Laserthermia Systems AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.

www.clinicallaser.se

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: CLS-B.ST

View More

Performance Overview: CLS-B.ST

Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

CLS-B.ST
28.42%
OMX Stockholm 30 Index (^OMX)
0.14%

1-Year Return

CLS-B.ST
84.84%
OMX Stockholm 30 Index (^OMX)
6.13%

3-Year Return

CLS-B.ST
98.50%
OMX Stockholm 30 Index (^OMX)
22.82%

5-Year Return

CLS-B.ST
98.98%
OMX Stockholm 30 Index (^OMX)
59.41%

Compare To: CLS-B.ST

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CLS-B.ST

View More

Valuation Measures

Annual
As of 5/23/2025
  • Market Cap

    67.25M

  • Enterprise Value

    39.59M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.34

  • Price/Book (mrq)

    0.91

  • Enterprise Value/Revenue

    1.97

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -250.51%

  • Return on Assets (ttm)

    -40.94%

  • Return on Equity (ttm)

    -85.15%

  • Revenue (ttm)

    20.14M

  • Net Income Avi to Common (ttm)

    -50.45M

  • Diluted EPS (ttm)

    -3.0900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    27.87M

  • Total Debt/Equity (mrq)

    0.32%

  • Levered Free Cash Flow (ttm)

    -36.76M

Research Analysis: CLS-B.ST

View More

Company Insights: CLS-B.ST

Research Reports: CLS-B.ST

View More

People Also Watch